PTHS Earnings

PTHS reported its earnings on 2025-11-13, showcasing a revenue of 7.41M against an estimate of 4.38M, resulting in a 69.14% surprise. The EPS was -5.3, surpassing the expected -0.67 by -691.04%. The stock experienced a -7.27% price change on the earnings day and a -14.91% change over the next five days, reflecting market reactions to the results.

Following PTHS's earnings announcement on 2025-11-13, the stock price moved by -7.27% on the day of the release. Over the subsequent five days, it saw a -14.91% change. Historically, PTHS's stock price tends to shift by an average of -4.12% in the 10 days leading up to earnings and -18.11% in the 10 days following, providing insight into potential market.

For , analysts estimate PTHS's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PTHS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PTHS's stock price typically moves by -4.12% in the 10 days before its earnings and -18.11% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call reveals strong financial performance with a significant revenue increase, improved operating and EBITDA losses, and a higher cash balance. The Q&A highlights strategic growth plans, competitive positioning, and market expansion. Despite some uncertainties in management responses, the overall sentiment is positive due to strong growth drivers, increased prescriber adoption, and anticipated profitability by year-end. The expected rise in GTN discounts and SG&A expenses is offset by the positive revenue and demand trends, suggesting a likely positive stock price movement over the next two weeks.